Sharon Anderson
Vice President, Scientific Affairs Alliance for Regenerative Medicine
Sharon Anderson is Vice President for Scientific Affairs at the Alliance for Regenerative Medicine (ARM). She joined the organization in 2025, bringing more than 20 years of leadership experience in cell therapy, immuno-oncology, and manufacturing operations. Her expertise spans research and development, manufacturing, technology transfer, and advanced analytical methods. At ARM, Sharon leads the 2026 CAR-T Access Coalition and helps drive cross-sector engagement among scientific leaders to shape best practices and advance the CGT field.
Seminars
Automated manufacturing is emerging as the industry’s clearest path to lower COGs, broader patient access and sustainable commercial success.
In this focused session, evaluate where automation delivers the greatest value in your manufacturing process, how to integrate it into your existing framework and how to align with regulations. Through case studies and in-depth discussions, combining industry leaders involved in automated manufacturing and key regulatory experts, gain insight into the decisions, trade-offs and lessons shaping automated manufacturing programmes to de-risk execution and ensure a smooth and economical road to market.
- Analyzing the impact of automation on cost of goods to optimize resource allocation and support sustainable clinical and commercial manufacturing
- Integrating automated platforms within GMP manufacturing and quality systems while maintaining data integrity and oversight
- Interpreting updated cell therapy GMP and advanced manufacturing technology expectations to leverage regulatory flexibility without compromising compliance
- Interpreting updated cell therapy GMP and advanced manufacturing technology expectations to leverage regulatory flexibility without compromising compliance
- Examining how evolving regulatory guidance influences clinical outcomes and commercialization pathways to align manufacturing quality with long-term market success
- Summarizing trends in recent CGT FDA decisions
- Sharing new tools and platform technologies of interest at the FDA
- Diving into FDA trends and future direction
